885069-14-7

Basic information

• Product Name: N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide
• Synonyms: N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide;AcetaMide,N-[6-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-2-benzothiazolyl]-
• CAS NO: 885069-14-7
• Molecular Formula: C₁₅H₁₉BN₂O₃S
• Molecular Weight: 318
• Mol File: 885069-14-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide(885069-14-7)
• EPA Substance Registry System: N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide(885069-14-7)

Safety Data

• Hazardous Substances Data: 885069-14-7(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide is used as a building block for the synthesis of pharmaceuticals or bioactive molecules due to its unique structure and functional groups. Its benzothiazole moiety and boron-containing group contribute to its potential as a precursor in the development of new drugs.
Used in Organic Synthesis:
In the field of organic synthesis, N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide is used for cross-coupling reactions. The boron-containing functional group allows for the formation of new carbon-carbon or carbon-heteroatom bonds, which are essential in creating complex organic molecules.
Used in Pharmaceutical Development:
N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide is used in the pharmaceutical industry as a potential source of new drug candidates. The benzothiazole moiety, which is known to be present in various pharmacologically active compounds, suggests that N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide may have biological activities that could be harnessed for therapeutic purposes.
Used in Bioactive Molecule Synthesis:
For the synthesis of bioactive molecules, N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide serves as a valuable intermediate. Its unique structure allows for the creation of molecules with potential biological activity, which can be further explored and optimized for specific applications in medicine and biology.

Upstream product

• 15864-32-1 2-amino-6-bromobenzothiazole 
• 73183-34-3 bis(pinacol)diborane 
• 106-40-1 4-bromo-aniline 
• 16628-26-5 N-(6-bromo-1,3-benzothiazol-2-yl)acetamide 

Downstream Products

• 1112980-20-7 N-(6-(1H-indazol-4-yl)-1,3-benzothiazol-2-yl)acetamide 
• 1112982-55-4 N-(6-(6-(2-fluorophenylsulfonyl)pyridin-2-yl)benzo[d]thiazol-2-yl)acetamide 
• 1112979-81-3 N-(6-(2-((4-methoxyphenyl)sulfonyl)-1,3-thiazol-5-yl)-1,3-benzothiazol-2-yl)acetamide 
• 1112979-86-8 N-(6-(6-((4-fluorophenyl)sulfonyl)-2-pyridinyl)-1,3-benzothiazol-2-yl)acetamide 
• 1112979-89-1 N-(6-(6-((4-methoxyphenyl)sulfonyl)-2-pyridinyl)-1,3-benzothiazol-2-yl)acetamide 
• 1112979-92-6 N-(6-(2-amino-1,3-benzothiazol-6-yl)-2-pyridinyl)benzenesulfonamide 
• 1112979-95-9 N-(6-(6-(methyl((4-methylphenyl)sulfonyl)amino)-2-pyridinyl)-1,3-benzothiazol-2-yl)acetamide 
• 1112980-18-3 N-(6-(2-((4-fluorophenyl)sulfonyl)-1,3-thiazol-4-yl)-1,3-benzothiazol-2-yl)acetamide 
• 1112980-86-5 N-(2-chloro-5-(2-acetylaminobenzo[d]thiazol-6-yl)pyridin-3-yl)-4-fluorophenylsulfonamide 
• 1112980-87-6 N-(6-(6-chloro-5-(4-methoxyphenylsulfonamido)pyridin-3-yl)benzo[d]thiazol-2-yl)acetamide 
• 1112981-20-0 N-(6-(5-(((4-methylphenyl)sulfonyl)amino)-3-pyridinyl)-1,3-benzothiazol-2-yl)acetamide 
• 1112981-46-0 N-(6-(5-(methyl((4-(trifluoromethyl)phenyl)sulfonyl)amino)-3-pyridinyl)-1,3-benzothiazol-2-yl)acetamide 
• 1112981-53-9 N-(6-(6-(methyl((3-methylphenyl)sulfonyl)amino)-2-pyridinyl)-1,3-benzothiazol-2-yl)acetamide 
• 1112981-89-1 N-(6-(5-(((4-(1-hydroxyethyl)phenyl)sulfonyl)amino)-3-pyridinyl)-1,3-benzothiazol-2-yl)acetamide 

Relevant articles and documents

HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF

The present disclosure provides heteroaryl compounds of formulas (I), (Ia) and (Ib), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosi

Medicine with necrocytosis inhibitory activity and application thereof

The invention provides a medicine with the necrocytosis inhibitory activity. The medicine with the necrocytosis inhibitory activity contains one or two of the following compounds. The invention further provides application of the medicine with the necrocy

MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF

Selective mTOR inhibitors of formulas (I)-(III), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from abnormal cell growth, functions, or behaviors mediated by an mTOR kinase and/or one or more PI3K enzyme, are provided. Such diseases and disorder include cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

Enhanced treatment regimens using mTor inhibitors

The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.

Benzothiazole Kinase Inhibitors and Methods of Use

The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PI3 kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.

Structural basis for isoform selectivity in a class of benzothiazole inhibitors of phosphoinositide 3-kinase γ

Phosphoinositide 3-kinase γ (PI3Kγ) is an attractive target to potentially treat a range of disease states. Herein, we describe the evolution of a reported phenylthiazole pan-PI3K inhibitor into a family of potent and selective benzothiazole inhibitors. U

Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors

Abstract Vismodegib is the first FDA approved cancer therapy based on inhibition of aberrant hedgehog signaling. Like most cancer therapies, vismodegib suffered from resistance, even during clinical development. Numerous reports demonstrated that simultan

COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY

Provided is a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a urea derivative shown in the present specification, or a pharmaceutically acceptable salt thereof.